Anti-OLM2A/ OLFML2A/ PRO34319 functional antibody
Anti-OLM2A/ OLFML2A/ PRO34319 functional antibody for cell culture, ELISA & in-vivo assay
Go to OLFML2A/OLFML2A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-SE0386-Ab-1/ GM-Tg-hg-SE0386-Ab-2 | Anti-Human OLFML2A monoclonal antibody | Human |
GM-Tg-rg-SE0386-Ab-1/ GM-Tg-rg-SE0386-Ab-2 | Anti-Rat OLFML2A monoclonal antibody | Rat |
GM-Tg-mg-SE0386-Ab-1/ GM-Tg-mg-SE0386-Ab-2 | Anti-Mouse OLFML2A monoclonal antibody | Mouse |
GM-Tg-cynog-SE0386-Ab-1/ GM-Tg-cynog-SE0386-Ab-2 | Anti-Cynomolgus/ Rhesus macaque OLFML2A monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-SE0386-Ab-1/ GM-Tg-felg-SE0386-Ab-2 | Anti-Feline OLFML2A monoclonal antibody | Feline |
GM-Tg-cang-SE0386-Ab-1/ GM-Tg-cang-SE0386-Ab-2 | Anti-Canine OLFML2A monoclonal antibody | Canine |
GM-Tg-bovg-SE0386-Ab-1/ GM-Tg-bovg-SE0386-Ab-2 | Anti-Bovine OLFML2A monoclonal antibody | Bovine |
GM-Tg-equg-SE0386-Ab-1/ GM-Tg-equg-SE0386-Ab-2 | Anti-Equine OLFML2A monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-SE0386-Ab-1/ GM-Tg-hg-SE0386-Ab-2; GM-Tg-rg-SE0386-Ab-1/ GM-Tg-rg-SE0386-Ab-2; GM-Tg-mg-SE0386-Ab-1/ GM-Tg-mg-SE0386-Ab-2; GM-Tg-cynog-SE0386-Ab-1/ GM-Tg-cynog-SE0386-Ab-2; GM-Tg-felg-SE0386-Ab-1/ GM-Tg-felg-SE0386-Ab-2; GM-Tg-cang-SE0386-Ab-1/ GM-Tg-cang-SE0386-Ab-2; GM-Tg-bovg-SE0386-Ab-1/ GM-Tg-bovg-SE0386-Ab-2; GM-Tg-equg-SE0386-Ab-1/ GM-Tg-equg-SE0386-Ab-2 |
Products Name | Anti-OLFML2A monoclonal antibody |
Format | mab |
Target Name | OLFML2A |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-OLFML2A benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-SE0386-Ag-1 | Recombinant multi-species OLM2A/ OLFML2A/ PRO34319 protein |
Target information
Target ID | GM-SE0386 |
Target Name | OLFML2A |
Gene ID | 169611,241327,296708,693790,491336,101081262,516730,100070961 |
Gene Symbol and Synonyms | 4932431K08Rik,mFLJ00237,OLFML2A,PRO34319 |
Uniprot Accession | Q68BL7 |
Uniprot Entry Name | OLM2A_HUMAN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000185585 |
Target Classification | N/A |
The target: OLFML2A, gene name: OLFML2A, also named as PRO34319. Predicted to enable extracellular matrix binding activity and identical protein binding activity. Predicted to act upstream of or within extracellular matrix organization. Predicted to be located in extracellular matrix and extracellular region. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.